dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%
- 1 March 2022
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (2) , 122-134
Abstract
No abstract availableKeywords
Funding Information
- EMD Serono
- AstraZeneca
- AbbVie
- Novartis
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company
- Pfizer
- Merck Sharp and Dohme United Kingdom
- Roche
This publication has 60 references indexed in Scilit:
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerLung Cancer, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Biomarkers associated with checkpoint inhibitorsAnnals of Oncology, 2016
- Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysisCancer Treatment Reviews, 2016
- Reduced naïve CD 8 + T ‐cell priming efficacy in elderly adultsAging Cell, 2015
- Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysisScientific Reports, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Immunologic and Clinical Effects of Targeting PD-1 in Lung CancerClinical Pharmacology & Therapeutics, 2014
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011